Details of the Drug Combination

General Information of Drug Combination (ID: DCREGW2)

Drug Combination Name
Verteporfin Aflibercept
Indication
Disease Entry Status REF
Macular Degeneration Phase 1 [1]
Component Drugs Verteporfin   DMIY6DB Aflibercept   DMT3D5I
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Verteporfin
Disease Entry ICD 11 Status REF
Choroidal neovascularization 9B76 Approved [2]
Exudative age-related macular degeneration 9B78.3Z Approved [2]
Psoriasis vulgaris EA90 Approved [3]
Verteporfin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
ATP-binding cassette sub-family B member 6 (ABCB6) DTF9Y2V ABCB6_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Indication(s) of Aflibercept
Disease Entry ICD 11 Status REF
Central retinal vein occlusion with macular edema N.A. Approved [4]
Diabetic macular edema 9B71.02 Approved [5]
Exudative age-related macular degeneration 9B78.3Z Approved [6]
Metastasis from malignant tumor of colon N.A. Approved [7]
Metastatic colorectal cancer 2B91 Approved [3]
Aflibercept Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [3]
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Modulator [3]
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01746875) A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
2 Verteporfin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
5 Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
6 Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
7 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e323-e328.
8 The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
9 Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.